Descripción del proyecto
Mejor comprensión del sistema ubicuitina
El sistema ubicuitina constituye una fuente prometedora de tratamientos de diversas enfermedades humanas que suponen un reto para la sociedad. Los motivos de secuencia lineal corta para interacciones, (SLiM, por sus siglas en inglés), representan una parte importante de los mecanismos que permiten utilizar el sistema ubicuitina para el tratamiento de ciertas enfermedades, si bien siguen siendo infrautilizados. El proyecto financiado con fondos europeos UBIMOTIF busca formar a investigadores noveles sobre los SLiM a través de un planteamiento multidisciplinario e intersectorial, así como con tecnología de vanguardia. El impacto de UBIMOTIF no tendrá precedentes, dado que proporcionará información sobre el sistema ubicuitina, así como nuevas oportunidades terapéuticas y una mano de obra cualificada que podrá llenar las carteras agotadas de las empresas europeas.
Objetivo
A major challenge is the lack of therapeutic approaches for numerous human diseases, which poses a societal challenge. The ubiquitin system is a major promising source for novel therapeutic approaches but its potential has not been fully exploited due to limited insight and lack of researchers trained in understanding and identifying avenues to target the ubiquitin system. Ubiquitin ligases and deubiquitinating enzymes (DUBs) comprises enzymes that actively add or remove ubiquitin from proteins to regulate cell physiology. How these enzymes selectively recognize their substrates is largely unknown but an emerging theme is that a globular domain in the enzyme binds a short linear interaction motif (SLiM) in the substrate. SLiMs are short peptide motifs that constitute ideal entry points for understanding the ubiquitin system as they provide detailed insight into substrate selection and how this regulates the underlying biology. Further, SLiMs provide direct routes to therapeutic exploitation as they serve as peptide scaffolds for drug development and tools to highjack the ubiquitin system. The potential of SLiMs has not been capitalized upon because a method for efficient identification was missing, interactions between relevant partners were lacking and this has hampered training of young researchers. UBIMOTIF overcomes these barriers by exploiting novel technological advances to identify SLiMs and uniting outstanding complementary researchers and industrial partners with a common vision to provide outstanding training of early career scientist in SLiMs and the ubiquitin system. The UBIMOTIF topic provides ideal training of young researchers, as it requires a multidisciplinary and intersectorial approach providing training in multiple cutting-edge technologies. The impact of UBIMOTIF will be unprecedented insight into the ubiquitin system, novel therapeutic opportunities and a skilled workforce that can fill the exhausted pipelines of European companies.
Ámbito científico
Programa(s)
Régimen de financiación
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinador
1165 Kobenhavn
Dinamarca